Clinical and microbiologic analysis of a hospital's extended-spectrum β-lactamase-producing isolates over a 2-year period

Pharmacotherapy

Volumn 23, Issue 10 II, 2003, Pages 1232-1237

  Burgess, David S ^a,b,d   Hall II, Ronald G ^a   Lewis II, James S ^a,b,c   Jorgensen, James H ^b   Patterson, Jan E ^b  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b University of Texas Health Science Center   (United States)

^c University Hospital   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; BETA LACTAMASE; CARBAPENEM DERIVATIVE; CEFOTETAN; COTRIMOXAZOLE; GATIFLOXACIN; GENTAMICIN; LEVOFLOXACIN; MEROPENEM; NITROFURANTOIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATE; BETA LACTAMASE PRODUCING BACTERIUM; CLINICAL ARTICLE; ESCHERICHIA COLI; FEMALE; HUMAN; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; MALE; NONHUMAN; TREATMENT FAILURE;

ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CROSS INFECTION; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HOSPITAL BED CAPACITY, 500 AND OVER; HOSPITALS, UNIVERSITY; HUMANS; KLEBSIELLA; KLEBSIELLA INFECTIONS; MICROBIAL SENSITIVITY TESTS; RETROSPECTIVE STUDIES;

EID: 0141531017     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.23.12.1232.32706     Document Type: Article

References (28)

1. Wong-Beringer A. Therapeutic challenges associated with extended-spectrum, β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Pharmacotherapy 2001;21:583-92.
2. Nathisuwan S, Burgess DS, Lewis JS. Extended-spectrum β-lactamases: epidemiology, detection, and treatment. Pharmacotherapy 2001;21:920-8.
3. Patterson DL. Extended-spectrum β-lactamases: the European experience. Curr Opin Infect Dis 2001;14:697-701.
4. Burgess DS. Comparison of in vitro activity of piperacillin/tazobactam, cefepime, imipenem, and meropenem against extended-spectrum β-lactamase (ESBL) and non-ESBL producing K. pneumoniae by time-kill methodology [abstr]. Pharmacotherapy 2001;21:1273.
5. Thomson KS, Moland ES. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum β-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2001;45:3548-54.
6. Rebuck JA, Keith M, Olsen KM, Fey PD, Bergmann KL, Rupp ME. In vitro activities of parenteral β-lactam antimicrobials against TEM-10-, TEM-26- and SHV-5-derived extended-spectrum β-lactamases expressed in an isogenic Escherichia coli host. J Antimicrob Chemother 2000;46:461-4.
7. Coudron PE, Moland ES, Thomson KS. Occurrence and detection of AmpC β-lactamases among Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates at a veterans medical center. J Clin Microbiol 2000;38:1791-6.
8. Bauernfeind A, Wagner S, Jungwirth R, Schneider I, Meyer D. A novel class C β-lactamase (FOX-2) in Escherichia coli conferring resistance to cephamycins. Antimicrob Agents Chemother 1997;41:2041-6.
9. Bou G, Oliver A, Ojeda M, Monzon C, Martinez-Beltran J. Molecular characterization of FOX-4, a new AmpC-type plasmid-mediated β-lactamase from an Escherichia coli strain isolated in Spain. Antimicrob Agents Chemother 2000;44:2549-53.
10. Gazouli M, Tzouvelekis LS, Vatopoulos AC, Tzelepi E. Transferrable class C β-lactamases in Escherichia coli strains isolated in Greek hospitals and characterization of two enzyme variants (LAT-3 and LAT-4) closely related to Citrobacter freundii AmpC β-lactamase. J Antimicrob Chemother 1998;42:419-25.
11. Fortineau N, Poirel L, Nordmann P. Plasmid-mediated and inducible cephalosporinase DHA-2 from Klebsiella pneumoniae. J Antimicrob Chemother 2001;47:207-10.
12. Queenan AM, Jenkins S, Bush K. Cloning and biochemical characterization of FOX-5, an AmpC-type plasmid-encoded β-lactamase from a New York City Klebsiella pneumoniae clinical isolate. Antimicrob Agents Chemother 2001;45:3189-94.
13. National Committee for Clinical Laboratory Standards. Methods for dilution: antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard, 5th ed. NCCLS document M7-A5. Wayne, PA: National Committee for Clinical Laboratory Standards, 2000.
14. Paterson DL, Ko WC, Von Gottberg A, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001;39:2206-12.
15. Quale JM, Landman D, Bradford PA, et al. Molecular epidemiology of a citywide outbreak of extended-spectrum β-lactamase-producing Klebsiella pneumoniae infection. Clin Infect Dis 2002;35:834-41.
16. Jean S, Teng L, Hsueh P, Ho S, Luh K. Antimicrobial susceptibilities among clinical isolates of extended-spectrum cephalosporin-resistant gram-negative bacteria in a Taiwanese university hospital. J Antimicrob Chemother 2002;49:69-76.
17. Jett BD, Ritchie DJ, Reichley R, Bailey TC, Sahm DF. In vitro activities of various β-lactam antimicrobial agents against clinical isolates of Escherichia coli and Klebsiella spp. resistant to oxyimino cephalosporins. Antimicrob Agents Chemother 1995;39:1187-90.
18. Leleu G, Kitzis MD, Vallois JM, Gutmann L, Decazes JM. Different ratios of piperacillin-tazobactam combination for treatment of experimental meningitis due to Klebsiella pneumoniae producing the TEM-3 extended-spectrum β-lactamase. Antimicrob Agents Chemother 1994;38:195-9.
19. Mentec H, Vallois JM, Bure A, Saleh-Mghir A, Jehl F, Carbon C. Piperacillin/tazobactam, and gentamicin alone or combined in an endocarditis model of infection by a TEM-3-producing strain of Klebsiella pneumoniae or its susceptible variant. Antimicrob Agents Chemother 1992;36:1883-9.
20. Rice LB, Carias LL, Shlaes DM. In vivo efficacies of β-lactam/β -lactamase inhibitor combinations against a TEM-26-producing strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 1994;38:2663-4.
21. Thauvin-Elliopoulos C, Tripodi MF, Moellering RC, Eliopoulos GM. Efficacies of piperacillin-tazobactam and cefepime in rats with experimental intra-abdominal abscesses due to an extended-spectrum β -lactamase-producing strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 1997;41:1053-7.
22. Paterson DL, Singh N, Gayowski T, Marino IR. Fatal infection due to extended-spectrum β-lactamase-producing Escherichia coli: implications for antibiotic choice for spontaneous bacterial peritonitis. Clin Infect Dis 1999;28:683-4.
23. Patterson JE, Hardin TC, Kelly CA, Garcia RC, Jorgensen JH. Association of antibiotic utilization measures and control of multiple-drug resistance in Klebsiella pneumoniae. Infect Control Hosp Epidemiol 2000;21:455-8.
24. Wong-Beringer A, Hindler J, Queenan AM, et al. Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime. Clin Infect Dis 2002;34:135-46.
25. Meyer KS, Urban C, Eagan JA, Berger BJ, Rahal JJ. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med 1993;119:353-8.
26. Rice LB, Eckstein EC, DeVente J, Shlaes DM. Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center. Clin Infect Dis 1996;23:118-24.
27. Rahal JJ, Urban C, Horn D, et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA 1998;280:1233-7.
28. Kim YK, Pai H, Lee HJ, et al. Bloodstream infections by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome. Antimicrob Agents Chemother 2002;46:1481-91.